2aof › Citations

Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT
FEBS J 272 5265-77 (2005)
Related entries: 2aoc, 2aod, 2aoe, 2aog, 2aoh, 2aoi, 2aoj

Cited: 53 times
EuropePMC logo PMID: 16218957

Abstract

HIV-1 protease (PR) and two drug-resistant variants--PR with the V82A mutation (PR(V82A)) and PR with the I84V mutation (PR(I84V))--were studied using reduced peptide analogs of five natural cleavage sites (CA-p2, p2-NC, p6pol-PR, p1-p6 and NC-p1) to understand the structural and kinetic changes. The common drug-resistant mutations V82A and I84V alter residues forming the substrate-binding site. Eight crystal structures were refined at resolutions of 1.10-1.60 A. Differences in the PR-analog interactions depended on the peptide sequence and were consistent with the relative inhibition. Analog p6(pol)-PR formed more hydrogen bonds of P2 Asn with PR and fewer van der Waals contacts at P1' Pro compared with those formed by CA-p2 or p2-NC in PR complexes. The P3 Gly in p1-p6 provided fewer van der Waals contacts and hydrogen bonds at P2-P3 and more water-mediated interactions. PR(I84V) showed reduced van der Waals interactions with inhibitor compared with PR, which was consistent with kinetic data. The structures suggest that the binding affinity for mutants is modulated by the conformational flexibility of the substrate analogs. The complexes of PR(V82A) showed smaller shifts of the main chain atoms of Ala82 relative to PR, but more movement of the peptide analog, compared to complexes with clinical inhibitors. PR(V82A) was able to compensate for the loss of interaction with inhibitor caused by mutation, in agreement with kinetic data, but substrate analogs have more flexibility than the drugs to accommodate the structural changes caused by mutation. Hence, these structures help to explain how HIV can develop drug resistance while retaining the ability of PR to hydrolyze natural substrates.

Articles - 2aof mentioned but not cited (1)

  1. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT. FEBS J 272 5265-5277 (2005)


Reviews citing this publication (5)

  1. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. Ghosh AK, Osswald HL, Prato G. J Med Chem 59 5172-5208 (2016)
  2. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. Lefebvre E, Schiffer CA. AIDS Rev 10 131-142 (2008)
  3. Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. Ghosh AK, Anderson DD, Weber IT, Mitsuya H. Angew Chem Int Ed Engl 51 1778-1802 (2012)
  4. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Li G, De Clercq E. Microbiol Mol Biol Rev 80 679-731 (2016)
  5. Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease. Dakshinamoorthy A, Asmita A, Senapati S. ACS Omega 8 9748-9763 (2023)

Articles citing this publication (47)

  1. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. J Mol Biol 363 161-173 (2006)
  2. HIV-1 Protease: Structural Perspectives on Drug Resistance. Weber IT, Agniswamy J. Viruses 1 1110-1136 (2009)
  3. Molecular Basis for Drug Resistance in HIV-1 Protease. Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MNL, Nalivaika EA, Özen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA. Viruses 2 2509-2535 (2010)
  4. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. Shen CH, Wang YF, Kovalevsky AY, Harrison RW, Weber IT. FEBS J 277 3699-3714 (2010)
  5. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Agniswamy J, Shen CH, Aniana A, Sayer JM, Louis JM, Weber IT. Biochemistry 51 2819-2828 (2012)
  6. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. Sayer JM, Liu F, Ishima R, Weber IT, Louis JM. J Biol Chem 283 13459-13470 (2008)
  7. A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. Giffin MJ, Heaslet H, Brik A, Lin YC, Cauvi G, Wong CH, McRee DE, Elder JH, Stout CD, Torbett BE. J Med Chem 51 6263-6270 (2008)
  8. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. Liu F, Boross PI, Wang YF, Tozser J, Louis JM, Harrison RW, Weber IT. J Mol Biol 354 789-800 (2005)
  9. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT. Proteins 67 232-242 (2007)
  10. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. Liu F, Kovalevsky AY, Tie Y, Ghosh AK, Harrison RW, Weber IT. J Mol Biol 381 102-115 (2008)
  11. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. Ghosh AK, Leshchenko-Yashchuk S, Anderson DD, Baldridge A, Noetzel M, Miller HB, Tie Y, Wang YF, Koh Y, Weber IT, Mitsuya H. J Med Chem 52 3902-3914 (2009)
  12. Comparative studies on retroviral proteases: substrate specificity. Tözsér J. Viruses 2 147-165 (2010)
  13. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW, Weber IT. J Med Chem 50 4509-4515 (2007)
  14. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. Liu F, Kovalevsky AY, Louis JM, Boross PI, Wang YF, Harrison RW, Weber IT. J Mol Biol 358 1191-1199 (2006)
  15. Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT. Biochemistry 46 14854-14864 (2007)
  16. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Altman MD, Nalivaika EA, Prabu-Jeyabalan M, Schiffer CA, Tidor B. Proteins 70 678-694 (2008)
  17. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. Ghosh AK, Kulkarni S, Anderson DD, Hong L, Baldridge A, Wang YF, Chumanevich AA, Kovalevsky AY, Tojo Y, Amano M, Koh Y, Tang J, Weber IT, Mitsuya H. J Med Chem 52 7689-7705 (2009)
  18. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. Ghosh AK, Gemma S, Baldridge A, Wang YF, Kovalevsky AY, Koh Y, Weber IT, Mitsuya H. J Med Chem 51 6021-6033 (2008)
  19. Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study. Mosebi S, Morris L, Dirr HW, Sayed Y. J Virol 82 11476-11479 (2008)
  20. Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance. Chaudhury S, Gray JJ. Structure 17 1636-1648 (2009)
  21. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. Eizert H, Bander P, Bagossi P, Sperka T, Miklóssy G, Boross P, Weber IT, Tözsér J. J Virol 82 10111-10117 (2008)
  22. Binding kinetics and substrate selectivity in HIV-1 protease-Gag interactions probed at atomic resolution by chemical exchange NMR. Deshmukh L, Tugarinov V, Louis JM, Clore GM. Proc Natl Acad Sci U S A 114 E9855-E9862 (2017)
  23. In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking. Bolstad ES, Anderson AC. Proteins 75 62-74 (2009)
  24. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights. Chetty S, Bhakat S, Bhakat S, Martin AJ, Soliman ME. J Biomol Struct Dyn 34 135-151 (2016)
  25. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. Ghosh AK, Chapsal BD, Parham GL, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H. J Med Chem 54 5890-5901 (2011)
  26. Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease. Liu Z, Wang Y, Brunzelle J, Kovari IA, Kovari LC. Protein J 30 173-183 (2011)
  27. [Reversal of multidrug resistance of gastric cancer cells by down-regulation of CIAPIN1 with CIAPIN1 siRNA]. Li X, Fan R, Zou X, Hong L, Gao L, Jin H, Du R, He L, Xia L, Fan D. Mol Biol (Mosk) 42 102-109 (2008)
  28. Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease. Ishima R, Gong Q, Tie Y, Weber IT, Louis JM. Proteins 78 1015-1025 (2010)
  29. Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability. Ode H, Yokoyama M, Kanda T, Sato H. J Mol Model 17 391-399 (2011)
  30. Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease. Dirauf P, Meiselbach H, Sticht H. J Mol Model 16 1577-1583 (2010)
  31. Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues. Agniswamy J, Kneller DW, Brothers R, Wang YF, Harrison RW, Weber IT. ACS Omega 4 8707-8719 (2019)
  32. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism. Meher BR, Wang Y. J Mol Graph Model 56 60-73 (2015)
  33. Understanding HIV-1 protease autoprocessing for novel therapeutic development. Huang L, Chen C. Future Med Chem 5 1215-1229 (2013)
  34. Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes. Liu Z, Wang Y, Yedidi RS, Dewdney TG, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Biochem Biophys Res Commun 430 1022-1027 (2013)
  35. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. Ghosh AK, Gemma S, Takayama J, Baldridge A, Leshchenko-Yashchuk S, Miller HB, Wang YF, Kovalevsky AY, Koh Y, Weber IT, Mitsuya H. Org Biomol Chem 6 3703-3713 (2008)
  36. Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Alvizo O, Mittal S, Mayo SL, Schiffer CA. Protein Sci 21 1029-1041 (2012)
  37. Capturing the reaction pathway in near-atomic-resolution crystal structures of HIV-1 protease. Shen CH, Tie Y, Yu X, Wang YF, Kovalevsky AY, Harrison RW, Weber IT. Biochemistry 51 7726-7732 (2012)
  38. Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies. Honarparvar B, Makatini MM, Pawar SA, Petzold K, Soliman ME, Arvidsson PI, Sayed Y, Govender T, Maguire GE, Kruger HG. ChemMedChem 7 1009-1019 (2012)
  39. Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease. Wang Y, Dewdney TG, Liu Z, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC. Biology (Basel) 1 81-93 (2012)
  40. Structural basis for a hand-like site in the calcium sensor CatchER with fast kinetics. Zhang Y, Reddish F, Tang S, Zhuo Y, Wang YF, Yang JJ, Weber IT. Acta Crystallogr D Biol Crystallogr 69 2309-2319 (2013)
  41. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. Ghosh AK, Sean Fyvie W, Brindisi M, Steffey M, Agniswamy J, Wang YF, Aoki M, Amano M, Weber IT, Mitsuya H. Bioorg Med Chem Lett 27 4925-4931 (2017)
  42. Proven in vitro evolution of protease cathepsin E-inhibitors and -activators at pH 4.5 using a paired peptide method. Kitamura K, Komatsu M, Biyani M, Futakami M, Kawakubo T, Yamamoto K, Nishigaki K. J Pept Sci 18 711-719 (2012)
  43. Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17. Agniswamy J, Kneller DW, Ghosh AK, Weber IT. Biochem Biophys Res Commun 566 30-35 (2021)
  44. Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition. Vanangamudi M, Nair PC, Engels SEM, Palaniappan S, Namasivayam V. Adv Exp Med Biol 1322 63-95 (2021)
  45. A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease. Windsor IW, Raines RT. Acta Crystallogr D Struct Biol 74 690-694 (2018)
  46. Elasticity-Associated Functionality and Inhibition of the HIV Protease. Sherry D, Worth R, Sayed Y. Adv Exp Med Biol 1371 79-108 (2022)
  47. Refinement of a low-resolution crystal structure to better understand erythromycin interactions on large ribosomal subunit. Wahab HA, Yam WK, Samian MR, Najimudin N. J Biomol Struct Dyn 26 131-146 (2008)


Quick links